122 related articles for article (PubMed ID: 16465035)
1. [The pathophysiology of osteoporosis/osteopenia in gene mutant mice].
Kobayashi Y; Takahashi N
Clin Calcium; 2006 Feb; 16(2):311-18. PubMed ID: 16465035
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
3. Genetic control of bone remodeling--insights from a rare disease.
Krane SM
N Engl J Med; 2002 Jul; 347(3):210-2. PubMed ID: 12124412
[No Abstract] [Full Text] [Related]
4. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
Hofbauer LC; Heufelder AE
Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
[No Abstract] [Full Text] [Related]
5. Osteoprotegerin deficiency and juvenile Paget's disease.
Whyte MP; Obrecht SE; Finnegan PM; Jones JL; Podgornik MN; McAlister WH; Mumm S
N Engl J Med; 2002 Jul; 347(3):175-84. PubMed ID: 12124406
[TBL] [Abstract][Full Text] [Related]
6. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
Middleton-Hardie C; Zhu Q; Cundy H; Lin JM; Callon K; Tong PC; Xu J; Grey A; Cornish J; Naot D
J Bone Miner Res; 2006 Mar; 21(3):438-45. PubMed ID: 16491292
[TBL] [Abstract][Full Text] [Related]
7. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
Whyte MP
Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin deficiency and juvenile Paget's disease.
Hofbauer LC; Schoppet M
N Engl J Med; 2002 Nov; 347(20):1622-3; author reply 1622-3. PubMed ID: 12432053
[No Abstract] [Full Text] [Related]
9. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease.
Hofbauer LC; Schoppet M
J Clin Endocrinol Metab; 2002 Sep; 87(9):4078-9. PubMed ID: 12213849
[No Abstract] [Full Text] [Related]
11. [Genetic background of osteoporosis].
Takács I; Lakatos P
Orv Hetil; 2003 Jul; 144(30):1467-72. PubMed ID: 14569676
[TBL] [Abstract][Full Text] [Related]
12. Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation.
Glass DA; Karsenty G
Ann N Y Acad Sci; 2006 Apr; 1068():117-30. PubMed ID: 16831912
[TBL] [Abstract][Full Text] [Related]
13. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children.
Hartikka H; Mäkitie O; Männikkö M; Doria AS; Daneman A; Cole WG; Ala-Kokko L; Sochett EB
J Bone Miner Res; 2005 May; 20(5):783-9. PubMed ID: 15824851
[TBL] [Abstract][Full Text] [Related]
14. [Osteoporosis and cardiovascular disease--two sides of the same coin?].
Nawroth P; Pirzer R; Fohr B; Schilling T; Ziegler R; Bierhaus A; Kasperk C
Med Klin (Munich); 2003 Aug; 98(8):437-46. PubMed ID: 12928809
[TBL] [Abstract][Full Text] [Related]
15. [Future therapies for metabolic bone diseases. New concepts and targets].
Nemec K; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2001; 30(6):548-52. PubMed ID: 11715689
[No Abstract] [Full Text] [Related]
16. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype.
Chong B; Hegde M; Fawkner M; Simonet S; Cassinelli H; Coker M; Kanis J; Seidel J; Tau C; Tüysüz B; Yüksel B; Love D;
J Bone Miner Res; 2003 Dec; 18(12):2095-104. PubMed ID: 14672344
[TBL] [Abstract][Full Text] [Related]
18. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
19. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
Mori H; Kitazawa R; Mizuki S; Nose M; Maeda S; Kitazawa S
Histochem Cell Biol; 2002 Mar; 117(3):283-92. PubMed ID: 11914926
[TBL] [Abstract][Full Text] [Related]
20. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
